Showing results (411-420 of 576) with videos related to

Sort By:
Pageof 58
Cancer|March 7, 2023
Association between bariatric surgery and outcomes in chronic myeloid leukemiaFadi G Haddad, Hagop M Kantarjian, Aram Bidikian, et al.
American Journal of Hematology|March 31, 2022
Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitorsFadi G Haddad, Koji Sasaki, Ghayas C Issa, et al.
Leukemia & Lymphoma|August 7, 2020
Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 yearsCatherine Kendall Major, Hagop Kantarjian, Koji Sasaki, et al.
Leukemia & Lymphoma|November 28, 2024
Azacitidine and venetoclax with or without pevonedistat in patients with newly diagnosed acute myeloid leukemiaNicholas J Short, Agnieszka Wierzbowska, Thomas Cluzeau, et al.
Leukemia|September 25, 2024
Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia and lymphomaFarhad Ravandi, Jayastu Senapati, Nitin Jain, et al.
Acta Haematologica|June 19, 2022
A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating MutationsSai Prasad Desikan, Farhad Ravandi, Naveen Pemmaraju, et al.
Leukemia|June 21, 2020
The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemiaMansour Alfayez, Ghayas C Issa, Keyur P Patel, et al.
American Journal of Hematology|August 5, 2021
Development of TP53 mutations over the course of therapy for acute myeloid leukemiaYasmin Alwash, Joseph D Khoury, Mehrnoosh Tashakori, et al.
Cancer|December 7, 2018
Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypesPrajwal C Boddu, Tapan M Kadia, Guillermo Garcia-Manero, et al.
Blood Cancer Journal|June 27, 2026
Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemiaElias Jabbour, Caitlin R Rausch, Hannah Goulart, et al.
Pageof 58